Separate terms with OR to return results that match either term.
 
Clear All
700 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year (Ascending) FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C9165 Elranatamab-bcmm Elrexfio 1mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2023 Dec. 7, 2023 In Use
J9286 Glofitamab-gxbm Columvi 2.5mg Immunotherapy Monoclonal Antibody CD20, CD3 No 2023 Dec. 7, 2023 In Use
J9321 Epcoritamab-bysp Epkinly 0.16mg Immunotherapy Monoclonal Antibody CD20, CD3 No 2023 Dec. 7, 2023 In Use
J9324 Pemetrexed disodium Pemrydi-rtu 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2023 Dec. 7, 2023 In Use
Futibatinib Lytgobi 4mg Chemotherapy Tyrosine Kinase Inhibitor FGFR Yes 2023 In Use
Momelotinib Ojjaara Multiple Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2023 In Use
Niraparib and Abiraterone Akeega Multiple Chemotherapy Androgen Receptor Inhibitor, Enzyme Inhibitor CYP 17, PARP Yes 2023 In Use
NA Pirtobrutinib Jaypirca Multiple Chemotherapy Tyrosine Kinase Inhibitor BTK Yes 2023 In Use
NA Quizartinib Vanflyta Multiple Chemotherapy Tyrosine Kinase Inhibitor FLT3 Yes 2023 In Use
NA Elacestrant Orserdu Multiple Hormonal Therapy Estrogen Receptor Antagonist ERÉ‘ Yes 2023 In Use

Found 700 results in 2 milliseconds — Export these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.